Unknown

Dataset Information

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.


ABSTRACT:

Importance

The most useful biomarkers for clinical decision-making identify patients likely to have improved outcomes with one treatment vs another.

Objective

To evaluate treatment class-specific outcomes of patients receiving immune checkpoint inhibitor (ICI) vs taxane chemotherapy by tumor mutational burden (TMB).

Design, setting, and participants

This comparative effectiveness analysis of clinical variables and outcomes used prospectively defined biomarker-stratified genomic data from a deidentified clinicogenomic database. Data included men with previously treated metastatic castration-resistant prostate cancer (mCRPC) receiving ICI or single-agent taxane chemotherapy from January 2011 to April 2021 at approximately 280 US academic or community-based cancer clinic

SUBMITTER: Graf RP 

PROVIDER: S-EPMC8972027 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature